摘要
The development of immune checkpoint inhibitors(ICIs)was a milestone in the advancement of anticancer treatment.ICIs exert their effects by enhancing the function of T cells via inhibition of immune checkpoints,such as programmed cell death protein-1(PD-1)/programmed cell death-ligand 1(PDL1).
基金
supported by the 1·3·5 Project for Disciplines of Excellence-Clinical Research Incubation Project,West China Hospital,Sichuan University(2020HXFH046)
Regional Innovation Cooperation Project of Sichuan Science and Technology Program(2021YFQ0029)
the National Natural Science Foundation of China(82103413)。
